SCHEMBL4706345

SCHEMBL4706345

Cc1ccc(C(=O)Nc2cccc(C(=O)c3ccc4c(c3)NC(=O)C4=CNc3ccc(N4CCN(C)CC4)cc3)c2)cc1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NTRK1 P04629 4/20 0.54
NTRK3 Q16288 1/20 0.54
RAB9A P51151 6/20 0.52
NPC1 O15118 5/20 0.52
NTRK2 Q16620 3/20 0.48
CSF1R P07333 1/20 0.47
F10 P00742 2/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
MAPT P10636 2/20 0.45
KDM4E B2RXH2 1/20 0.45
MEN1 O00255 1/20 0.45
LMNA P02545 1/20 0.45
KMT2A Q03164 1/20 0.45
MCL1 Q07820 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
FLT3 P36888 1/20 0.44
AURKB Q96GD4 1/20 0.44
ALDH1A1 P00352 1/20 0.42
CYP2C9 P11712 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4758964 1.00 NTRK1 (0.54) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4757936 0.95 NPC1 (0.52) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4757933 0.95 NPC1 (0.52) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4758073 0.95 NTRK1 (0.55) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4703080 0.95 NTRK1 (0.55) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4755255 0.94 CSF1R (0.54) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4755254 0.94 CSF1R (0.54) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4757095 0.93 NTRK1 (0.50) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4757094 0.93 NTRK1 (0.50) NTRK1NTRK3RAB9ANPC1NTRK2
SCHEMBL4758867 0.92 NTRK1 (0.49) NTRK1NTRK3RAB9ANPC1NTRK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1902025-A1 KINASE INHIBITORS Allergan, Inc. (US) 2008-03-26 EP claimed
US-20070032478-A1 Kinase Inhibitors ALLERGAN, INC. 2007-02-08 US claimed
WO-2007008895-A1 KINASE INHIBITORS ALLERGAN, INC. (US) 2007-01-18 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070032478-A1 Kinase Inhibitors ABL1, LCK, ERBB2 NTRK1 413/4885NTRK3 418/4885RAB9A 2799/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.